{
    "info": {
        "nct_id": "NCT05577000",
        "official_title": "A Phase 1b Clinical Trial of Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma",
        "inclusion_criteria": "1. Voluntarily sign informed consent form\n2. >=18 years of age at the time of signing informed consent\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n4. Diagnosis of MM with relapsed or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor (PI; e.g., bortezomib or carfilzomib) immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide), and anti-CD38 antibody therapy\n5. Participants must have measurable disease, including at least one of the criteria below:\n\n   1. Serum M-protein greater or equal to 0.5 g/dL.\n   2. Urine M-protein greater or equal to 200 mg/24 h.\n   3. Serum free light chain (FLC) assay: involved FLC level of >= 100 mg/L.\n6. Adequate organ function, defined as:\n\n   1. Hemoglobulin >8 gm/dl (transfusions allowed).\n   2. Platelets >50,000/microliter (uL) (in the absence of platelet transfusion within 7 days of apheresis, but transfusion permitted prior to lymphodepleting chemotherapy).\n   3. Absolute neutrophil count (ANC) > 1000/uL in the absence of growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days of apheresis, but growth factor permitted prior to lymphodepleting chemotherapy).\n   4. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN).\n   5. Total bilirubin =< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome.\n   6. Serum creatinine clearance (CrCl) >= 45 mL/min using Cockcroft-Gault formula.\n   7. Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA).\n7. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of contraception for 1 year after the last dose of anti-BCMA CAR-T cells.\n8. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Autologous transplant within 6 weeks of planned CAR-T cell infusion.\n2. Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast). Any fully treated malignancies or indolent, clinically insignificant malignancies can be discussed among the study team to determine eligibility.\n3. HIV seropositivity.\n4. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded).\n5. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements.\n6. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test.\n7. Patients with currently symptomatic central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia, and Parkinson's disease.\n8. History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.\n\nEligibility for Infusion of Investigational Product:\n\nIncludes the inclusion/exclusion criteria required for enrollment with the following exceptions and additions.\n\nInclusion criteria exceptions:\n\n1. Hematologic function parameters will not be included as a pre-infusion eligibility criterion (because lymphodepletive chemotherapy is expected to cause pancytopenia).\n2. Laboratory result abnormalities that are considered not clinically significant by the principal investigator, AND are not the result of a demonstrated active infection or an active central nervous system condition.\n\nExclusion criteria additions:\n\n1. Use of anti-multiple myeloma therapy, including systemic corticosteroids within 14 days prior to lymphodepletive chemotherapy.\n2. Neurologic symptoms suggestive of an active central nervous system condition.",
        "miscellaneous_criteria": "Eligibility for enrollment:"
    },
    "inclusion_lines": [
        {
            "line": "1. Hemoglobulin >8 gm/dl (transfusions allowed).",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobulin >8 gm/dl",
                    "criterion": "hemoglobulin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "gm/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Urine M-protein greater or equal to 200 mg/24 h.",
            "criterions": [
                {
                    "exact_snippets": "Urine M-protein greater or equal to 200 mg/24 h",
                    "criterion": "urine M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 h"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Voluntarily sign informed consent form",
            "criterions": [
                {
                    "exact_snippets": "Voluntarily sign informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. >=18 years of age at the time of signing informed consent",
            "criterions": [
                {
                    "exact_snippets": ">=18 years of age at the time of signing informed consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at time of signing informed consent",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Total bilirubin =< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome.",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome.",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dl x institutional ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "except with Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Diagnosis of MM with relapsed or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor (PI; e.g., bortezomib or carfilzomib) immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide), and anti-CD38 antibody therapy",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of MM",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have had at least 3 different prior lines of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including proteasome inhibitor (PI; e.g., bortezomib or carfilzomib)",
                    "criterion": "prior proteasome inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide)",
                    "criterion": "prior immunomodulatory therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anti-CD38 antibody therapy",
                    "criterion": "prior anti-CD38 antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelets >50,000/microliter (uL) (in the absence of platelet transfusion within 7 days of apheresis, but transfusion permitted prior to lymphodepleting chemotherapy).",
            "criterions": [
                {
                    "exact_snippets": "Platelets >50,000/microliter (uL)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50000,
                                "unit": "microliter"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of platelet transfusion within 7 days of apheresis",
                    "criterion": "platelet transfusion within 7 days of apheresis",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Adequate organ function, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants must have measurable disease, including at least one of the criteria below:",
            "criterions": [
                {
                    "exact_snippets": "Participants must have measurable disease",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including at least one of the criteria below",
                    "criterion": "at least one of the criteria below",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum M-protein greater or equal to 0.5 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Serum M-protein greater or equal to 0.5 g/dL",
                    "criterion": "serum M-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method.",
            "criterions": [
                {
                    "exact_snippets": "Males who have partners of childbearing potential",
                    "criterion": "male participant's partner childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use an effective barrier contraceptive method",
                    "criterion": "contraceptive method use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use barrier contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of contraception for 1 year after the last dose of anti-BCMA CAR-T cells.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (defined as all women physiologically capable of becoming pregnant)",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum or urine pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use highly effective methods of contraception for 1 year after the last dose of anti-BCMA CAR-T cells",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Absolute neutrophil count (ANC) > 1000/uL in the absence of growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days of apheresis, but growth factor permitted prior to lymphodepleting chemotherapy).",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) > 1000/uL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1000,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days of apheresis",
                    "criterion": "growth factor support (filgrastim or pegfilgrastim)",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "filgrastim within 7 days of apheresis",
                                "pegfilgrastim within 14 days of apheresis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Serum creatinine clearance (CrCl) >= 45 mL/min using Cockcroft-Gault formula.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine clearance (CrCl) >= 45 mL/min using Cockcroft-Gault formula.",
                    "criterion": "serum creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Serum free light chain (FLC) assay: involved FLC level of >= 100 mg/L.",
            "criterions": [
                {
                    "exact_snippets": "Serum free light chain (FLC) assay: involved FLC level of >= 100 mg/L.",
                    "criterion": "involved serum free light chain (FLC) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA).",
            "criterions": [
                {
                    "exact_snippets": "Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 40%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "echocardiogram",
                                "multiple uptake gated acquisition (MUGA)"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. HIV seropositivity.",
            "criterions": [
                {
                    "exact_snippets": "HIV seropositivity",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast). Any fully treated malignancies or indolent, clinically insignificant malignancies can be discussed among the study team to determine eligibility.",
            "criterions": [
                {
                    "exact_snippets": "Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast)",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "non-melanoma skin cancer",
                                "carcinoma in situ (e.g., cervix, bladder, or breast)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Includes the inclusion/exclusion criteria required for enrollment with the following exceptions and additions.",
            "criterions": [
                {
                    "exact_snippets": "Includes the inclusion/exclusion criteria required for enrollment",
                    "criterion": "inclusion/exclusion criteria for enrollment",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Autologous transplant within 6 weeks of planned CAR-T cell infusion.",
            "criterions": [
                {
                    "exact_snippets": "Autologous transplant within 6 weeks of planned CAR-T cell infusion.",
                    "criterion": "autologous transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... are excluded",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding women are excluded ... breastfeeding should be discontinued",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential must have a negative serum or urine pregnancy test",
                    "criterion": "pregnancy test result in women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Patients with currently symptomatic central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia, and Parkinson's disease.",
            "criterions": [
                {
                    "exact_snippets": "currently symptomatic central nervous system (CNS) pathology",
                    "criterion": "central nervous system (CNS) pathology",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "epilepsy",
                    "criterion": "epilepsy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "seizure disorders",
                    "criterion": "seizure disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "paresis",
                    "criterion": "paresis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "aphasia",
                    "criterion": "aphasia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled cerebrovascular disease",
                    "criterion": "cerebrovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe brain injuries",
                    "criterion": "brain injuries",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "dementia",
                    "criterion": "dementia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Parkinson's disease",
                    "criterion": "Parkinson's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded).",
            "criterions": [
                {
                    "exact_snippets": "Serologic status reflecting active hepatitis B or C infection",
                    "criterion": "active hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B core antibody",
                    "criterion": "hepatitis B core antibody",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for ... hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for ... hepatitis C antibody",
                    "criterion": "hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded)",
                    "criterion": "hepatitis B or C PCR",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Laboratory result abnormalities that are considered not clinically significant by the principal investigator, AND are not the result of a demonstrated active infection or an active central nervous system condition.",
            "criterions": [
                {
                    "exact_snippets": "Laboratory result abnormalities that are considered not clinically significant by the principal investigator",
                    "criterion": "laboratory result abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance (per principal investigator)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "are not the result of a demonstrated active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "cause of laboratory result abnormalities",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "are not the result of ... an active central nervous system condition",
                    "criterion": "active central nervous system condition",
                    "requirements": [
                        {
                            "requirement_type": "cause of laboratory result abnormalities",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement of immunosuppressive medication within 6 months",
                    "criterion": "immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "requirement/use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Hematologic function parameters will not be included as a pre-infusion eligibility criterion (because lymphodepletive chemotherapy is expected to cause pancytopenia).",
            "criterions": [
                {
                    "exact_snippets": "Hematologic function parameters will not be included as a pre-infusion eligibility criterion",
                    "criterion": "hematologic function parameters",
                    "requirements": [
                        {
                            "requirement_type": "inclusion as pre-infusion eligibility criterion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary abnormalities",
                    "criterion": "pulmonary abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Neurologic symptoms suggestive of an active central nervous system condition.",
            "criterions": [
                {
                    "exact_snippets": "Neurologic symptoms suggestive of an active central nervous system condition",
                    "criterion": "neurologic symptoms suggestive of an active central nervous system condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Use of anti-multiple myeloma therapy, including systemic corticosteroids within 14 days prior to lymphodepletive chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Use of anti-multiple myeloma therapy ... within 14 days prior to lymphodepletive chemotherapy.",
                    "criterion": "anti-multiple myeloma therapy",
                    "requirements": [
                        {
                            "requirement_type": "use within time window before lymphodepletive chemotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including systemic corticosteroids within 14 days prior to lymphodepletive chemotherapy.",
                    "criterion": "systemic corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "use within time window before lymphodepletive chemotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Eligibility for Infusion of Investigational Product:",
            "criterions": [
                {
                    "exact_snippets": "Eligibility for Infusion of Investigational Product",
                    "criterion": "eligibility for infusion of investigational product",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Eligibility for enrollment:",
            "criterions": [
                {
                    "exact_snippets": "Eligibility for enrollment",
                    "criterion": "eligibility for enrollment",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [
        {
            "line": "4. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "Inclusion criteria exceptions:",
            "criterions": []
        },
        {
            "line": "Exclusion criteria additions:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}